QNRX VS EVOK Stock Comparison

Performance

QNRX
10/100

QNRX returned -81.93% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

EVOK
23/100

EVOK returned -16.77% in the last 12 months. Based on SPY's performance of -13.16%, its performance is below average giving it a score of 22 of 100.

Technicals

QNRX
29/100

QNRX receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

EVOK
64/100

EVOK receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

QNRX
10/100

QNRX has missed earnings 5 times in the last 20 quarters.

EVOK
10/100

EVOK has missed earnings 11 times in the last 20 quarters.

Profit

QNRX
10/100

Out of the last 14 quarters, QNRX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

EVOK
10/100

Out of the last 20 quarters, EVOK has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

QNRX
35/100

QNRX has had a lower than average amount of volatility over the last 12 months giving it a score of 35 of 100.

EVOK
54/100

EVOK has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

Analyst Price Targets

QNRX

"Analyst Price Targets" not found for QNRX

EVOK
75/100

5 analysts offer 12-month price targets for EVOK. Together, they have an average target of 0, the most optimistic target put EVOK at 0 within 12-months and the most pessimistic has EVOK at 0.

All score calculations are broken down here to help you make more informed investing decisions

Quoin Pharmaceuticals, Ltd. American Depositary Shares Summary

Nasdaq / QNRX

Healthcare

Biotechnology

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Evoke Pharma, Inc. Summary

Nasdaq / EVOK

Healthcare

Drug Manufacturers - Specialty & Generic

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Power up your portfolio